1 Wilson, M. H. & Collier, A. M. Ultrastructural study of Mycoplasma pneumoniae in organ culture. Journal of bacteriology 125, 332-339, doi:10.1128/JB.125.1.332-339.1976 (1976).
2 Waites, K. B., Xiao, L., Liu, Y., Balish, M. F. & Atkinson, T. P. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clinical microbiology reviews 30, 747-809, doi:10.1128/CMR.00114-16 (2017).
3 Lindsey, J. R. & Cassell, H. Experimental Mycoplasma pulmonis infection in pathogen-free mice. Models for studying mycoplasmosis of the respiratory tract. The American journal of pathology 72, 63-90 (1973).
4 Lin, J. H., Chen, S. P., Yeh, K. S. & Weng, C. N. Mycoplasma hyorhinis in Taiwan: diagnosis and isolation of swine pneumonia pathogen. Veterinary microbiology 115, 111-116, doi:10.1016/j.vetmic.2006.02.004 (2006).
5 Parker, A. M., Sheehy, P. A., Hazelton, M. S., Bosward, K. L. & House, J. K. A review of mycoplasma diagnostics in cattle. Journal of veterinary internal medicine 32, 1241-1252, doi:10.1111/jvim.15135 (2018).
6 Horner, P. J. & Martin, D. H. Mycoplasma genitalium Infection in Men. The Journal of infectious diseases 216, S396-S405, doi:10.1093/infdis/jix145 (2017).
7 Mardh, P. A. Mycoplasma hominis infection of the central nervous system in newborn infants. Sexually transmitted diseases 10, 331-334 (1983).
8 Parrott, G. L., Kinjo, T. & Fujita, J. A Compendium for Mycoplasma pneumoniae. Frontiers in microbiology 7, 513, doi:10.3389/fmicb.2016.00513 (2016).
9 Foy, H. M., Kenny, G. E., Cooney, M. K. & Allan, I. D. Long-term epidemiology of infections with Mycoplasma pneumoniae. The Journal of infectious diseases 139, 681-687, doi:10.1093/infdis/139.6.681 (1979).
10 Jain, S. et al. Community-acquired pneumonia requiring hospitalization among U.S. children. The New England journal of medicine 372, 835-845, doi:10.1056/NEJMoa1405870 (2015).
11 Zhao, C., Liu, J., Yang, H., Xiang, L. & Zhao, S. Mycoplasma pneumoniae- Associated Bronchiolitis Obliterans Following Acute Bronchiolitis. Scientific reports 7, 8478, doi:10.1038/s41598-017-08861-7 (2017).
12 Tanaka, H. Correlation between Radiological and Pathological Findings in Patients with Mycoplasma pneumoniae Pneumonia. Frontiers in microbiology 7, 695, doi:10.3389/fmicb.2016.00695 (2016).
13 Waites, K. B. & Talkington, D. F. Mycoplasma pneumoniae and its role as a human pathogen. Clinical microbiology reviews 17, 697-728, table of contents, doi:10.1128/CMR.17.4.697-728.2004 (2004).
14 Atkinson, T. P., Balish, M. F. & Waites, K. B. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS microbiology reviews 32, 956-973, doi:10.1111/j.1574-6976.2008.00129.x (2008).
15 Lamoth, F. & Greub, G. Fastidious intracellular bacteria as causal agents of community-acquired pneumonia. Expert review of anti-infective therapy 8, 775- 790, doi:10.1586/eri.10.52 (2010).
16 Ozel, C. et al. [Mycoplasma Pneumoniae-Induced Meningoencephalitis]. Fortschritte der Neurologie-Psychiatrie 83, 392-396, doi:10.1055/s-0035-1553233 (2015).
17 Atkinson, T. P. & Waites, K. B. Mycoplasma pneumoniae Infections in Childhood. The Pediatric infectious disease journal 33, 92-94, doi:10.1097/INF.0000000000000171 (2014).
18 Fan, Q. et al. Pathogenesis and association of Mycoplasma pneumoniae infection with cardiac and hepatic damage. Microbiology and immunology 59, 375-380, doi:10.1111/1348-0421.12267 (2015).
19 Meyer Sauteur, P. M. et al. Infection with and Carriage of Mycoplasma pneumoniae in Children. Frontiers in microbiology 7, 329, doi:10.3389/fmicb.2016.00329 (2016).
20 Zhao, F. et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrobial agents and chemotherapy 57, 1521-1523, doi:10.1128/AAC.02060-12 (2013).
21 Katsukawa, C., Kenri, T., Shibayama, K. & Takahashi, K. Genetic characterization of Mycoplasma pneumoniae isolated in Osaka between 2011 and 2017: Decreased detection rate of macrolide-resistance and increase of p1 gene type 2 lineage strains. PloS one 14, e0209938, doi:10.1371/journal.pone.0209938 (2019).
22 Sanchez, A. R., Rogers, R. S., 3rd & Sheridan, P. J. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. International journal of dermatology 43, 709-715, doi:10.1111/j.1365-4632.2004.02108.x (2004).
23 Adefurin, A., Sammons, H., Jacqz-Aigrain, E. & Choonara, I. Ciprofloxacin safety in paediatrics: a systematic review. Archives of disease in childhood 96, 874-880, doi:10.1136/adc.2010.208843 (2011).
24 Oishi, T. et al. Clinical implications of interleukin-18 levels in pediatric patients with Mycoplasma pneumoniae pneumonia. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 17, 803- 806, doi:10.1007/s10156-011-0265-7 (2011).
25 Shimizu, T. Inflammation-inducing Factors of Mycoplasma pneumoniae. Frontiers in microbiology 7, 414, doi:10.3389/fmicb.2016.00414 (2016).
26 Takeuchi, O. et al. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. Journal of immunology 164, 554-557, doi:10.4049/jimmunol.164.2.554 (2000).
27 Chen, Z. et al. Role of the Mycoplasma pneumoniae/Interleukin-8/Neutrophil Axis in the Pathogenesis of Pneumonia. PloS one 11, e0146377, doi:10.1371/journal.pone.0146377 (2016).
28 Mashimoto, H. et al. [Acute bronchiolitis due to Mycoplasma pneumoniae and successfully treated with steroids]. Nihon Kyobu Shikkan Gakkai zasshi 34, 1277-1282 (1996).
29 Smith, C. B., Chanock, R. M., Friedewald, W. T. & Alford, R. H. Mycoplasma pneumoniae infections in volunteers. Annals of the New York Academy of Sciences 143, 471-483, doi:10.1111/j.1749-6632.1967.tb27691.x (1967).
30 Smith, C. B., Friedewald, W. T. & Chanock, R. M. Inactivated Mycoplasma pneumoniae vaccine. Evaluation in volunteers. Jama 199, 353-358 (1967).
31 Chiang, W. C. et al. Epidemiology, clinical characteristics and antimicrobial resistance patterns of community-acquired pneumonia in 1702 hospitalized children in Singapore. Respirology 12, 254-261, doi:10.1111/j.1440- 1843.2006.01036.x (2007).
32 Okada, T. et al. A practical approach estimating etiologic agents using real-time PCR in pediatric inpatients with community-acquired pneumonia. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 18, 832-840, doi:10.1007/s10156-012-0422-7 (2012).
33 Oishi, T. et al. Comparing Antimicrobial Susceptibilities among Mycoplasma pneumoniae Isolates from Pediatric Patients in Japan between Two Recent Epidemic Periods. Antimicrobial agents and chemotherapy 63, doi:10.1128/AAC.02517-18 (2019).
34 Saraya, T. et al. Identification of a mechanism for lung inflammation caused by Mycoplasma pneumoniae using a novel mouse model. Results in immunology 1, 76-87, doi:10.1016/j.rinim.2011.11.001 (2011).
35 Looney, M. R. & Matthay, M. A. Neutrophil sandwiches injure the microcirculation. Nature medicine 15, 364-366, doi:10.1038/nm0409-364 (2009).
36 Yamamoto, T., Kida, Y., Sakamoto, Y. & Kuwano, K. Mpn491, a secreted nuclease of Mycoplasma pneumoniae, plays a critical role in evading killing by neutrophil extracellular traps. Cellular microbiology 19, doi:10.1111/cmi.12666 (2017).
37 Lai, J. F. et al. Critical role of macrophages and their activation via MyD88- NFkappaB signaling in lung innate immunity to Mycoplasma pneumoniae. PloS one 5, e14417, doi:10.1371/journal.pone.0014417 (2010).
38 Shimizu, T. et al. Cytadherence of Mycoplasma pneumoniae induces inflammatory responses through autophagy and toll-like receptor 4. Infection and immunity 82, 3076-3086, doi:10.1128/IAI.01961-14 (2014).
39 Kannan, T. R. & Baseman, J. B. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proceedings of the National Academy of Sciences of the United States of America 103, 6724-6729, doi:10.1073/pnas.0510644103 (2006).
40 Li, G. et al. High co-expression of TNF-alpha and CARDS toxin is a good predictor for refractory Mycoplasma pneumoniae pneumonia. Molecular medicine 25, 38, doi:10.1186/s10020-019-0105-2 (2019).
41 Hardy, R. D. et al. Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin. PloS one 4, e7562, doi:10.1371/journal.pone.0007562 (2009).
42 Medina, J. L. et al. Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation. American journal of respiratory cell and molecular biology 46, 815-822, doi:10.1165/rcmb.2011-0135OC (2012).
43 Kannan, T. R. et al. Synthesis and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a murine model. The Journal of infectious diseases 204, 1596-1604, doi:10.1093/infdis/jir557 (2011).
44 Kannan, T. R. et al. Mycoplasma pneumoniae Community Acquired Respiratory Distress Syndrome toxin expression reveals growth phase and infection- dependent regulation. Molecular microbiology 76, 1127-1141, doi:10.1111/j.1365-2958.2010.07092.x (2010).
45 Forman, H. J. & Torres, M. Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. American journal of respiratory and critical care medicine 166, S4-8, doi:10.1164/rccm.2206007 (2002).
46 Prasad, S., Gupta, S. C. & Tyagi, A. K. Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. Cancer letters 387, 95-105, doi:10.1016/j.canlet.2016.03.042 (2017).
47 Camhi, S. L., Lee, P. & Choi, A. M. The oxidative stress response. New horizons 3, 170-182 (1995).
48 Sato, N. et al. Thiol-mediated redox regulation of apoptosis. Possible roles of cellular thiols other than glutathione in T cell apoptosis. Journal of immunology 154, 3194-3203 (1995).
49 Jabs, T. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochemical pharmacology 57, 231-245, doi:10.1016/s0006-2952(98)00227-5 (1999).
50 Bose, S. et al. ADP-ribosylation of NLRP3 by Mycoplasma pneumoniae CARDS toxin regulates inflammasome activity. mBio 5, doi:10.1128/mBio.02186-14 (2014).
51 He, J. et al. Insights into the pathogenesis of Mycoplasma pneumoniae (Review). Molecular medicine reports 14, 4030-4036, doi:10.3892/mmr.2016.5765 (2016).
52 Ichikawa, S., Miyake, M., Fujii, R. & Konishi, Y. MyD88 associated ROS generation is crucial for Lactobacillus induced IL-12 production in macrophage. PloS one 7, e35880, doi:10.1371/journal.pone.0035880 (2012).
53 Yang, C. S. et al. ASK1-p38 MAPK-p47phox activation is essential for inflammatory responses during tuberculosis via TLR2-ROS signalling. Cellular microbiology 10, 741-754, doi:10.1111/j.1462-5822.2007.01081.x (2008).
54 Kuroda, E. et al. Inhaled Fine Particles Induce Alveolar Macrophage Death and Interleukin-1alpha Release to Promote Inducible Bronchus-Associated Lymphoid Tissue Formation. Immunity 45, 1299-1310, doi:10.1016/j.immuni.2016.11.010 (2016).
55 Garlanda, C., Dinarello, C. A. & Mantovani, A. The interleukin-1 family: back to the future. Immunity 39, 1003-1018, doi:10.1016/j.immuni.2013.11.010 (2013).
56 Rock, K. L., Latz, E., Ontiveros, F. & Kono, H. The sterile inflammatory response. Annual review of immunology 28, 321-342, doi:10.1146/annurev-immunol- 030409-101311 (2010).
57 Suwara, M. I. et al. IL-1alpha released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts. Mucosal immunology 7, 684-693, doi:10.1038/mi.2013.87 (2014).
58 Caffrey, A. K. et al. IL-1alpha signaling is critical for leukocyte recruitment after pulmonary Aspergillus fumigatus challenge. PLoS pathogens 11, e1004625, doi:10.1371/journal.ppat.1004625 (2015).
59 Eigenbrod, T., Park, J. H., Harder, J., Iwakura, Y. & Nunez, G. Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. Journal of immunology 181, 8194-8198, doi:10.4049/jimmunol.181.12.8194 (2008).
60 Lauw, F. N. et al. Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees. The Journal of infectious diseases 179, 646-652, doi:10.1086/314636 (1999).
61 Roark, C. L., Simonian, P. L., Fontenot, A. P., Born, W. K. & O'Brien, R. L. gammadelta T cells: an important source of IL-17. Current opinion in immunology 20, 353-357, doi:10.1016/j.coi.2008.03.006 (2008).
62 Wu, Q. et al. IL-23-dependent IL-17 production is essential in neutrophil recruitment and activity in mouse lung defense against respiratory Mycoplasma pneumoniae infection. Microbes and infection 9, 78-86, doi:10.1016/j.micinf.2006.10.012 (2007).
63 Fettelschoss, A. et al. Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proceedings of the National Academy of Sciences of the United States of America 108, 18055-18060, doi:10.1073/pnas.1109176108 (2011).
64 Guo, L., Liu, F., Lu, M. P., Zheng, Q. & Chen, Z. M. Increased T cell activation in BALF from children with Mycoplasma pneumoniae pneumonia. Pediatric pulmonology 50, 814-819, doi:10.1002/ppul.23095 (2015).
65 De Simone, M. et al. Host genetic background influences the response to the opportunistic Pseudomonas aeruginosa infection altering cell-mediated immunity and bacterial replication. PloS one 9, e106873, doi:10.1371/journal.pone.0106873 (2014).
66 Spagnuolo, L. et al. The host genetic background defines diverse immune- reactivity and susceptibility to chronic Pseudomonas aeruginosa respiratory infection. Scientific reports 6, 36924, doi:10.1038/srep36924 (2016).
67 Lore, N. I., Cigana, C., Sipione, B. & Bragonzi, A. The impact of host genetic background in the Pseudomonas aeruginosa respiratory infections. Mammalian genome : official journal of the International Mammalian Genome Society 29, 550-557, doi:10.1007/s00335-018-9753-8 (2018).
68 Davis, J. K. et al. Strain differences in susceptibility to murine respiratory mycoplasmosis in C57BL/6 and C3H/HeN mice. Infection and immunity 50, 647- 654, doi:10.1128/IAI.50.3.647-654.1985 (1985).
69 Boonyarattanasoonthorn, T., Elewa, Y. H. A., Tag-El-Din-Hassan, H. T., Morimatsu, M. & Agui, T. Profiling of cellular immune responses to Mycoplasma pulmonis infection in C57BL/6 and DBA/2 mice. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 73, 55-65, doi:10.1016/j.meegid.2019.04.019 (2019).
70 Faulkner, C. B. et al. Gene expression and production of tumor necrosis factor alpha, interleukin 1, interleukin 6, and gamma interferon in C3H/HeN and C57BL/6N mice in acute Mycoplasma pulmonis disease. Infection and immunity 63, 4084-4090, doi:10.1128/IAI.63.10.4084-4090.1995 (1995).
71 Blotz, C., Singh, N., Dumke, R. & Stulke, J. Characterization of an Immunoglobulin Binding Protein (IbpM) From Mycoplasma pneumoniae. Frontiers in microbiology 11, 685, doi:10.3389/fmicb.2020.00685 (2020).
72 Gosselin, D. et al. Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infection and immunity 63, 3272-3278, doi:10.1128/IAI.63.9.3272-3278.1995 (1995).
73 Wilson, K. R., Napper, J. M., Denvir, J., Sollars, V. E. & Yu, H. D. Defect in early lung defence against Pseudomonas aeruginosa in DBA/2 mice is associated with acute inflammatory lung injury and reduced bactericidal activity in naive macrophages. Microbiology 153, 968-979, doi:10.1099/mic.0.2006/002261-0 (2007).
74 Yadav, J. S. et al. Multigenic control and sex bias in host susceptibility to spore- induced pulmonary anthrax in mice. Infection and immunity 79, 3204-3215, doi:10.1128/IAI.01389-10 (2011).
75 Cerquetti, M. C., Sordelli, D. O., Ortegon, R. A. & Bellanti, J. A. Impaired lung defenses against Staphylococcus aureus in mice with hereditary deficiency of the fifth component of complement. Infection and immunity 41, 1071-1076, doi:10.1128/IAI.41.3.1071-1076.1983 (1983).
76 Whaley, K. & Schwaeble, W. Complement and complement deficiencies. Seminars in liver disease 17, 297-310, doi:10.1055/s-2007-1007206 (1997).
77 Wood, A. J. T., Vassallo, A., Summers, C., Chilvers, E. R. & Conway-Morris, A. C5a anaphylatoxin and its role in critical illness-induced organ dysfunction. European journal of clinical investigation 48, e13028, doi:10.1111/eci.13028 (2018).
78 Czermak, B. J. et al. Protective effects of C5a blockade in sepsis. Nature medicine 5, 788-792, doi:10.1038/10512 (1999).
79 Rittirsch, D. et al. Functional roles for C5a receptors in sepsis. Nature medicine 14, 551-557, doi:10.1038/nm1753 (2008).
80 Wetsel, R. A., Fleischer, D. T. & Haviland, D. L. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. The Journal of biological chemistry 265, 2435-2440 (1990).
81 Fels, A. O. & Cohn, Z. A. The alveolar macrophage. Journal of applied physiology 60, 353-369, doi:10.1152/jappl.1986.60.2.353 (1986).
82 Arredouani, M. et al. The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. The Journal of experimental medicine 200, 267-272, doi:10.1084/jem.20040731 (2004).
83 Arredouani, M. S. et al. MARCO is the major binding receptor for unopsonized particles and bacteria on human alveolar macrophages. Journal of immunology 175, 6058-6064, doi:10.4049/jimmunol.175.9.6058 (2005).
84 Liu, T., Matsuguchi, T., Tsuboi, N., Yajima, T. & Yoshikai, Y. Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice. Infection and immunity 70, 6638-6645, doi:10.1128/iai.70.12.6638-6645.2002 (2002).
85 Croxford, A. L., Kulig, P. & Becher, B. IL-12-and IL-23 in health and disease. Cytokine & growth factor reviews 25, 415-421, doi:10.1016/j.cytogfr.2014.07.017 (2014).
86 Bosmann, M., Sarma, J. V., Atefi, G., Zetoune, F. S. & Ward, P. A. Evidence for anti-inflammatory effects of C5a on the innate IL-17A/IL-23 axis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 26, 1640-1651, doi:10.1096/fj.11-199216 (2012).
87 Lajoie, S. et al. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nature immunology 11, 928-935, doi:10.1038/ni.1926 (2010).
88 Chu, H. W. et al. Repeated respiratory Mycoplasma pneumoniae infections in mice: effect of host genetic background. Microbes and infection 8, 1764-1772, doi:10.1016/j.micinf.2006.02.014 (2006).
89 Cimolai, N., Mah, D. G., Taylor, G. P. & Morrison, B. J. Bases for the early immune response after rechallenge or component vaccination in an animal model of acute Mycoplasma pneumoniae pneumonitis. Vaccine 13, 305-309, doi:10.1016/0264-410x(95)93318-4 (1995).
90 Fernald, G. W., Collier, A. M. & Clyde, W. A., Jr. Respiratory infections due to Mycoplasma pneumoniae in infants and children. Pediatrics 55, 327-335 (1975).
91 Dobbs, N. A., Odeh, A. N., Sun, X. & Simecka, J. W. The Multifaceted Role of T Cell-Mediated Immunity in Pathogenesis and Resistance to Mycoplasma Respiratory Disease. Current trends in immunology 10, 1-19 (2009).
92 Yang, M., Meng, F., Gao, M., Cheng, G. & Wang, X. Cytokine signatures associate with disease severity in children with Mycoplasma pneumoniae pneumonia. Scientific reports 9, 17853, doi:10.1038/s41598-019-54313-9 (2019).
93 Way, E. E., Chen, K. & Kolls, J. K. Dysregulation in lung immunity - the protective and pathologic Th17 response in infection. European journal of immunology 43, 3116-3124, doi:10.1002/eji.201343713 (2013).
94 Wang, X. et al. Increased Frequency of Th17 Cells in Children With Mycoplasma pneumoniae Pneumonia. Journal of clinical laboratory analysis 30, 1214-1219, doi:10.1002/jcla.22005 (2016).
95 Zhao, J., Ji, X., Wang, Y. & Wang, X. Clinical Role of Serum Interleukin-17A in the Prediction of Refractory Mycoplasma pneumoniae Pneumonia in Children. Infection and drug resistance 13, 835-843, doi:10.2147/IDR.S240034 (2020).
96 Hausner, M., Schamberger, A., Naumann, W., Jacobs, E. & Dumke, R. Development of protective anti-Mycoplasma pneumoniae antibodies after immunization of guinea pigs with the combination of a P1-P30 chimeric recombinant protein and chitosan. Microbial pathogenesis 64, 23-32, doi:10.1016/j.micpath.2013.07.004 (2013).
97 Zhu, C. et al. Protective immune responses in mice induced by intramuscular and intranasal immunization with a Mycoplasma pneumoniae P1C DNA vaccine. Canadian journal of microbiology 58, 644-652, doi:10.1139/w2012-041 (2012).
98 Mogabgab, W. J. Efficacy of inactivated Mycoplasma pneumoniae vaccine demonstrated by protection in large field trials. Annals of the New York Academy of Sciences 225, 453-461, doi:10.1111/j.1749-6632.1973.tb45669.x (1973).
99 Mogabgab, W. J. Acute respiratory illnesses in university (1962-1966), military and industrial (1962-1963) populations. The American review of respiratory disease 98, 359-379, doi:10.1164/arrd.1968.98.3.359 (1968).
100 Cimolai, N., Cheong, A. C., Morrison, B. J. & Taylor, G. P. Mycoplasma pneumoniae reinfection and vaccination: protective oral vaccination and harmful immunoreactivity after re-infection and parenteral immunization. Vaccine 14, 1479-1483, doi:10.1016/s0264-410x(96)00068-0 (1996).
101 Szczepanek, S. M. et al. Vaccination of BALB/c mice with an avirulent Mycoplasma pneumoniae P30 mutant results in disease exacerbation upon challenge with a virulent strain. Infection and immunity 80, 1007-1014, doi:10.1128/IAI.06078-11 (2012).
102 Kolaczkowska, E. & Kubes, P. Neutrophil recruitment and function in health and inflammation. Nature reviews. Immunology 13, 159-175, doi:10.1038/nri3399 (2013).
103 Ye, P. et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. The Journal of experimental medicine 194, 519- 527, doi:10.1084/jem.194.4.519 (2001).
104 Kudva, A. et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. Journal of immunology 186, 1666-1674, doi:10.4049/jimmunol.1002194 (2011).
105 Okazaki, N. et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiology and immunology 45, 617-620, doi:10.1111/j.1348-0421.2001.tb01293.x (2001).
106 Suzuki, Y. et al. Multiple-Locus Variable-Number Tandem-Repeat Analysis of Mycoplasma pneumoniae Isolates between 2004 and 2014 in Yamagata, Japan: Change in Molecular Characteristics during an 11-year Period. Japanese journal of infectious diseases 70, 642-646, doi:10.7883/yoken.JJID.2017.276 (2017).
107 Sasaki, T. et al. Epidemiological study of Mycoplasma pneumoniae infections in japan based on PCR-restriction fragment length polymorphism of the P1 cytadhesin gene. Journal of clinical microbiology 34, 447-449, doi:10.1128/JCM.34.2.447-449.1996 (1996).
108 Kawai, Y. et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrobial agents and chemotherapy 57, 4046-4049, doi:10.1128/AAC.00663-13 (2013).
109 Dumke, R., Catrein, I., Pirkil, E., Herrmann, R. & Jacobs, E. Subtyping of Mycoplasma pneumoniae isolates based on extended genome sequencing and on expression profiles. International journal of medical microbiology : IJMM 292, 513-525, doi:10.1078/1438-4221-00231 (2003).
110 Gruson, D. et al. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrobial agents and chemotherapy 49, 1190-1193, doi:10.1128/AAC.49.3.1190-1193.2005 (2005).
論文の公開元へ
